BRPI0508798A - formulação lìquida de hormÈnio de crescimento, composição farmacêutica, forma de apresentação da formulação lìquida de hormÈnio de crescimento e uso da formulação lìquida de hormÈnio de crescimento - Google Patents

formulação lìquida de hormÈnio de crescimento, composição farmacêutica, forma de apresentação da formulação lìquida de hormÈnio de crescimento e uso da formulação lìquida de hormÈnio de crescimento

Info

Publication number
BRPI0508798A
BRPI0508798A BRPI0508798-8A BRPI0508798A BRPI0508798A BR PI0508798 A BRPI0508798 A BR PI0508798A BR PI0508798 A BRPI0508798 A BR PI0508798A BR PI0508798 A BRPI0508798 A BR PI0508798A
Authority
BR
Brazil
Prior art keywords
growth hormone
liquid growth
hormone formulation
formulation
pharmaceutical composition
Prior art date
Application number
BRPI0508798-8A
Other languages
English (en)
Portuguese (pt)
Inventor
Tudor Arvinte
Karine Luet Kleiber
Original Assignee
Ares Trading Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ares Trading Sa filed Critical Ares Trading Sa
Publication of BRPI0508798A publication Critical patent/BRPI0508798A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH] (Somatotropin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
BRPI0508798-8A 2004-04-07 2005-03-30 formulação lìquida de hormÈnio de crescimento, composição farmacêutica, forma de apresentação da formulação lìquida de hormÈnio de crescimento e uso da formulação lìquida de hormÈnio de crescimento BRPI0508798A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04101444 2004-04-07
PCT/EP2005/051448 WO2005105148A2 (en) 2004-04-07 2005-03-30 Liquid growth hormone formulation

Publications (1)

Publication Number Publication Date
BRPI0508798A true BRPI0508798A (pt) 2007-09-04

Family

ID=34928942

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0508798-8A BRPI0508798A (pt) 2004-04-07 2005-03-30 formulação lìquida de hormÈnio de crescimento, composição farmacêutica, forma de apresentação da formulação lìquida de hormÈnio de crescimento e uso da formulação lìquida de hormÈnio de crescimento

Country Status (24)

Country Link
US (1) US7662393B2 (de)
EP (1) EP1740213B9 (de)
JP (1) JP4991522B2 (de)
KR (1) KR101120879B1 (de)
CN (1) CN100574801C (de)
AT (1) ATE547121T1 (de)
AU (1) AU2005237775B2 (de)
BR (1) BRPI0508798A (de)
CA (1) CA2559918A1 (de)
CY (1) CY1113834T1 (de)
DK (1) DK1740213T3 (de)
EA (1) EA010626B1 (de)
ES (1) ES2383994T3 (de)
HK (1) HK1098708A1 (de)
HR (1) HRP20120235T1 (de)
IL (1) IL178416A (de)
MX (1) MXPA06011029A (de)
NO (1) NO337249B1 (de)
PL (1) PL1740213T3 (de)
PT (1) PT1740213E (de)
RS (1) RS52310B (de)
SI (1) SI1740213T1 (de)
UA (1) UA89781C2 (de)
WO (1) WO2005105148A2 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1174457B1 (de) * 1999-12-03 2004-12-22 Toray Industries, Inc. Biaxial gestreckte polyesterfolie zur formgebung
EP2142207A4 (de) * 2007-04-04 2013-01-16 Theratechnologies Inc Pharmazeutische formulierungen von ghrh-molekülen
EP2525833A2 (de) 2010-01-22 2012-11-28 Novo Nordisk Health Care AG Stabile wachstumshormonverbindungen
CN106139158A (zh) 2010-01-22 2016-11-23 诺沃—诺迪斯克保健股份有限公司 体内功效延长的生长激素
EP2417982A1 (de) * 2010-07-30 2012-02-15 Ferring B.V. Stabilisierung von Gonadotropinen
US20140194356A1 (en) 2011-07-25 2014-07-10 Sandoz Ag Aqueous formulation comprising at least a neutral salt and a biopharmaceutical protein
US8871713B2 (en) * 2013-03-01 2014-10-28 Theratechnologies Inc. Formulations of growth hormone releasing factor (GRF) molecules with improved stability
US11045523B2 (en) 2013-04-05 2021-06-29 Novo Nordisk Healthcare Ag Formulation of growth hormone albumin-binder conjugate
EP3431508A4 (de) * 2016-03-14 2019-08-14 JCR Pharmaceuticals Co., Ltd. Serumalbumin-20-k-wachstumshormonfusionprotein
US20200237652A1 (en) * 2017-08-08 2020-07-30 Csl Behring Ag Hemopexin formulations
WO2024026224A1 (en) 2022-07-29 2024-02-01 University Of Rochester Methods for improving muscle mass, strength, or function with a combination of testosterone and growth hormone

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3325223A1 (de) * 1983-07-13 1985-01-24 Hoechst Ag, 6230 Frankfurt Gegen denaturierung bestaendige, waessrige proteinloesungen, verfahren zu ihrer herstellung und ihre verwendung
JPS60123426A (ja) * 1983-12-07 1985-07-02 Eisai Co Ltd 経鼻投与用セクレチン製剤
DE3584560D1 (de) * 1984-04-09 1991-12-05 Du Pont Arzneimittelzusammensetzung geeignet zur behandlung oder prophylaxe von herzstoerungen.
PT83095B (en) * 1985-07-30 1987-12-23 Int Minerals & Chem Corp Method for the stabilization of growth promoting hormones using polyoxyethylene-polyoxypropylene copolymers
US5681814A (en) * 1990-06-07 1997-10-28 Genentech, Inc. Formulated IGF-I Composition
HUT67319A (en) * 1991-08-30 1995-03-28 Life Medical Sciences Inc Compositions for treating wounds
SE9201073D0 (sv) * 1992-04-03 1992-04-03 Kabi Pharmacia Ab Protein formulation
ATE359824T1 (de) * 1992-07-31 2007-05-15 Genentech Inc Wässrige formulierung enthaltend menschliches wachstumshormon
JPH0892125A (ja) * 1994-09-21 1996-04-09 Nippon Chem Res Kk 水性医薬組成物
AUPN801296A0 (en) * 1996-02-12 1996-03-07 Csl Limited Stabilised growth hormone formulation and method of preparation thereof
US20020077461A1 (en) * 1996-04-24 2002-06-20 Soren Bjorn Pharmaceutical formulation
US6759393B1 (en) * 1999-04-12 2004-07-06 Pfizer Inc. Growth hormone and growth hormone releasing hormone compositions
JP2003504346A (ja) * 1999-07-12 2003-02-04 グランデイス・バイオテツク・ゲー・エム・ベー・ハー 成長ホルモン製剤
EP1309312A2 (de) * 2000-08-07 2003-05-14 Inhale Therapeutic Systems, Inc. Inhalierbare sprühgetrocknete pulver aus proteinen die bündel aus 4 helices ausbilden mit minimierter aggregation
CA2466642C (en) * 2001-11-14 2011-01-18 Guohua Chen Injectable depot composition
AR040526A1 (es) * 2002-07-09 2005-04-13 Grandis Biotech Gmbh Formulaciuones de hgh en alta concentracion que contienen fenol
WO2004082707A2 (en) * 2003-03-18 2004-09-30 Ares Trading Sa Stabilisation of growth hormones in solution

Also Published As

Publication number Publication date
PL1740213T3 (pl) 2012-08-31
RS52310B (en) 2012-12-31
KR20070005628A (ko) 2007-01-10
NO337249B1 (no) 2016-02-22
EP1740213B1 (de) 2012-02-29
WO2005105148A3 (en) 2006-07-20
SI1740213T1 (sl) 2012-04-30
EP1740213B9 (de) 2012-06-13
UA89781C2 (uk) 2010-03-10
AU2005237775B2 (en) 2010-03-04
HK1098708A1 (en) 2007-07-27
WO2005105148A2 (en) 2005-11-10
KR101120879B1 (ko) 2012-02-27
WO2005105148A8 (en) 2005-12-08
IL178416A0 (en) 2007-02-11
EA200601874A1 (ru) 2007-02-27
JP4991522B2 (ja) 2012-08-01
ES2383994T3 (es) 2012-06-28
AU2005237775A1 (en) 2005-11-10
EA010626B1 (ru) 2008-10-30
IL178416A (en) 2012-12-31
CN100574801C (zh) 2009-12-30
US20080038292A1 (en) 2008-02-14
PT1740213E (pt) 2012-03-21
MXPA06011029A (es) 2007-01-25
NO20065097L (no) 2007-01-02
CA2559918A1 (en) 2005-11-10
DK1740213T3 (da) 2012-04-10
US7662393B2 (en) 2010-02-16
JP2007532515A (ja) 2007-11-15
EP1740213A2 (de) 2007-01-10
CN1946427A (zh) 2007-04-11
CY1113834T1 (el) 2016-07-27
ATE547121T1 (de) 2012-03-15
HRP20120235T1 (hr) 2012-04-30

Similar Documents

Publication Publication Date Title
BRPI0508798A (pt) formulação lìquida de hormÈnio de crescimento, composição farmacêutica, forma de apresentação da formulação lìquida de hormÈnio de crescimento e uso da formulação lìquida de hormÈnio de crescimento
BRPI0508579A (pt) composto, composição farmacêutica, e, uso de um composto
EP4249512A3 (de) Stabile antikörperformulierung
TR200002812T2 (tr) Efervesan formülasyonları.
WO2008057802A3 (en) Compositions comprising at least one acid labile proton pump inhibiting agents, optionally other pharmaceutically active agents and methods of using same
EA015464B9 (ru) Гербицидные составы с улучшенной эффективностью
PH12014502778A1 (en) Antibody formulation
TW200735897A (en) HFSH aqueous formulation
ECSP088962A (es) Nuevos herbicidas
TN2009000382A1 (en) Stable antibody formulations
WO2014096985A3 (en) A stable aqueous composition comprising human insulin or an analogue or derivative thereof
BR0114799A (pt) Compostos de ácido cianofenoxi carboxìlico e composições para liberar agentes ativos
WO2011118976A3 (en) Pharmaceutical composition for the prevention or the treatment of non-alcoholic fatty liver disease and the method for prevention or treatment of non-alcoholic fatty liver disease using the same
CY1111698T1 (el) Συνδυασμος που περιλαμβανει εναν ανταγωνιστη υποδοχεα ατ1 και εναν ενισχυτη εκκρισης ινσουλινης ή εναν ευαισθητοποιητη ινσουλινης
WO2008102349A3 (en) Terbinafine formulation for iontophoresis
TW200744993A (en) Crystalline forms of the di-sodium salt of N-(5-chlorosalicyloyl)-8-aminocaprylic acid
WO2004082707A3 (en) Stabilisation of growth hormones in solution
EA201490840A1 (ru) Препарат с замедленным высвобождением
ZA202204982B (en) Stable formulation of integrin antibody
CA2395438A1 (en) Dry compositions containing hydrophobic amino acid
WO2007034009A3 (es) Utilización de acido masónico como antiparasitario frente a protozoos del phyllum apicomplexa
TW200738141A (en) Aqueous suspension concentrates
WO2004105738A3 (en) Use of tetrahydropyridine derivatives
ATE424399T1 (de) Pharmazeutische zusammensetzungen von risperidon in wässriger lösung

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B11E Dismissal acc. art. 34 of ipl - requirements for examination incomplete
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B11T Dismissal of application maintained [chapter 11.20 patent gazette]